Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. ETF
  3. ASND
ASND logo

ASND

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewTechnicalNews
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

ASND News

FDA Grants Approvals for Multiple New Therapies

4d agoNASDAQ.COM

Ascendis Pharma Plans 2026 U.S. Launch of YUVIWEL Following FDA Approval

5d agoYahoo Finance

Ascendis Pharma A/S (ASND.US) Officer Plans to Sell $4.44 Million in Common Stock via Form 144

Mar 02 2026moomoo

Ascendis Pharma Receives FDA Approval for New Drug

Mar 02 2026Benzinga

Ascendis Pharma Receives FDA Accelerated Approval for YUVIWEL

Feb 28 2026NASDAQ.COM

FDA Approves Ascendis Pharma's Yuviwel for Dwarfism Treatment

Feb 28 2026seekingalpha

FDA Approves First Treatment for Achondroplasia

Feb 27 2026Newsfilter

Ascendis Pharma Receives FDA Approval for YUVIWEL, a Breakthrough Treatment for Achondroplasia

Feb 27 2026Yahoo Finance

Perceptive Advisors Acquires 431,432 Shares of Praxis Precision Medicines

Feb 22 2026Yahoo Finance

Perceptive Advisors Increases Stake in Celcuity

Feb 22 2026Yahoo Finance

BridgeBio Pharma Stock Soars on Positive Clinical Trial Results

Feb 12 2026Benzinga

Ascendis Pharma Reports Strong 2025 Financial Results and Growth Outlook

Feb 12 2026Yahoo Finance

Ascendis Pharma Reports Strong FY Earnings, Surpassing Expectations

Feb 11 2026seekingalpha

Ascendis Pharma Reports Strong 2025 Financial Results and Growth Outlook

Feb 11 2026Yahoo Finance

Ascendis Pharma Q4 Earnings Announcement Scheduled

Feb 10 2026seekingalpha

FDA Approves Zycubo for Pediatric Menkes Disease Treatment

Jan 28 2026NASDAQ.COM